Treatment for diabetes in patients inappropriate for metformin therapy
AssigneeBoehringer Ingelheim International GmbH
InventorsKlaus DUGI, Eva Ulrike GRAEFE-MODY, Ruth HARPER, Hans-Juergen WOERLE
Life of this patent
Estimating the term…
Abstract
The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
Claims25
A method for treating and/or preventing type 2 diabetes mellitus in a patient for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin comprising orally administering to the patient a DPP-4 inhibitor, which is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine or a pharmaceutically acceptable salt thereof, wherein said DPP-4 inhibitor is administered in an oral dose of 5 mg per day to said patient.
A method for treating type 2 diabetes mellitus in a patient with renal disease, renal impairment or renal dysfunction, comprising orally administering to the patient a DPP-4 inhibitor which is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a dose of 5 mg.
A method for treating type 2 diabetes mellitus in a patient with renal disease, renal impairment or renal dysfunction, comprising orally administering to the patient a DPP-4 inhibitor which is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a dose of 5 mg, wherein said DPP-4 inhibitor is used for said patient in the same dose as for a patient with normal renal function.
A method for treating type 2 diabetes mellitus in a patient having chronic renal insufficiency or impairment of moderate, severe or terminal stage, comprising orally administering to the patient a DPP-4 inhibitor which is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a dose of 5 mg once daily.
Dependencies are inferred from the claim text.